{"id":5123,"date":"2010-11-29T19:04:27","date_gmt":"2010-11-30T00:04:27","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5123"},"modified":"2011-07-19T17:44:41","modified_gmt":"2011-07-19T21:44:41","slug":"study-finds-no-link-between-cancer-and-antihypertensives-except-for-arb-ace-inhibitor-combo","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/11\/29\/study-finds-no-link-between-cancer-and-antihypertensives-except-for-arb-ace-inhibitor-combo\/","title":{"rendered":"Study Finds No Link Between Cancer and Antihypertensives, Except for ARB-ACE Inhibitor Combo"},"content":{"rendered":"<p>A new meta-analysis has found no evidence of a large cancer risk for most common antihypertensive agents, but did find strong evidence, largely based on one trial, for at least a 10% increase in cancer risk with the rarely used angiotensin-converting-enzyme (ACE) inhibitor and angiotensin-receptor blocker (ARB) combination. In a <a href=\"http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045%2810%2970260-6\/abstract\">paper in the <em>Lancet Oncology<\/em><\/a>, Sripal Bangalore and colleagues report on multiple analyses of data taken from 70 trials and including almost 325,000 patients.<\/p>\n<p>The results, write the authors, refute a 5% to 10% &#8220;increase in either cancer or cancer-related death with most antihypertensive drug classes.&#8221; In contrast to a previous study, the new meta-analysis did not find an increased risk for ARBs in general or for telmisartan specifically. For the ARB-ACE inhibitor combination, however, the investigators note &#8220;a consistent harmful effect,&#8221; though they point out that &#8220;the finding was driven largely by the ONTARGET trial.&#8221;<\/p>\n<p>Click <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/arbs-under-fire-perspectives-from-nissen-yancy-and-messerli\">here <\/a>for previous coverage of cancer and antihypertensive agents on CardioExchange.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new meta-analysis has found no evidence of a large cancer risk for most common antihypertensive agents, but did find strong evidence, largely based on one trial, for at least a 10% increase in cancer risk with the rarely used angiotensin-converting-enzyme (ACE) inhibitor and angiotensin-receptor blocker (ARB) combination. In a paper in the Lancet Oncology, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[590,416,454],"class_list":["post-5123","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-antihypertensive-agents","tag-cancer","tag-hypertension"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5123"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5123\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}